1h Free Analyst Time
Survival Motor Neuron Protein - Pipeline Review, H1 2020Speak directly to the analyst to clarify any post sales queries you may have.
Summary
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Survival of motor neuron or survival motor neuron (SMN) is a protein encoded by the SMN1 and SMN2 genes. The SMN complex plays a catalyst role in the assembly of small nuclear ribonucleoproteins (snRNPs). They play an important role in the splicing of cellular pre-mRNAs. They ensure the correct splicing of U12 intron-containing genes that is important for normal motor and proprioceptive neurons development. They are required for resolving RNA-DNA hybrids created by RNA polymerase II. They play a role in the metabolism of small nucleolar ribonucleoprotein.
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) pipeline Target constitutes close to 18 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 2 and 6 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 4 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System and Respiratory which include indications Spinal Muscular Atrophy (SMA), Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis.
The latest report Survival Motor Neuron Protein - Pipeline Review, H1 2020, outlays comprehensive information on the Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2)
- The report reviews Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Overview
- Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Companies Involved in Therapeutics Development
- AveXis Inc
- Biogen Inc
- Exicure Inc
- F. Hoffmann-La Roche Ltd
- Ionis Pharmaceuticals Inc
- Novartis AG
- Sarepta Therapeutics Inc
- Shift Pharmaceuticals
- Spotlight Innovation Inc
- Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Drug Profiles
- ALB-111 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Antisense Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- BIIB-089 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- branaplam - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- E-1V111 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Gene Therapy to Activate SMN for Spinal Muscular Atrophy - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- GTP-201 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- IONISENAC-2.5Rx - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- LDN-5178 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- onasemnogene abeparvovec - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- PMO-25 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Dormant Products
- Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Discontinued Products
- Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, H1 2020
- Number of Products under Development by Therapy Areas, H1 2020
- Number of Products under Development by Indication, H1 2020
- Number of Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Number of Products under Investigation by Universities/Institutes, H1 2020
- Products under Investigation by Universities/Institutes, H1 2020
- Number of Products by Stage and Mechanism of Actions, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Pipeline by AveXis Inc, H1 2020
- Pipeline by Biogen Inc, H1 2020
- Pipeline by Exicure Inc, H1 2020
- Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
- Pipeline by Ionis Pharmaceuticals Inc, H1 2020
- Pipeline by Novartis AG, H1 2020
- Pipeline by Sarepta Therapeutics Inc, H1 2020
- Pipeline by Shift Pharmaceuticals, H1 2020
- Pipeline by Spotlight Innovation Inc, H1 2020
- Dormant Projects, H1 2020
- Discontinued Products, H1 2020
List of Figures
- Number of Products under Development by Stage of Development, H1 2020
- Number of Products under Development by Therapy Areas, H1 2020
- Number of Products under Development by Top 10 Indications, H1 2020
- Number of Products by Stage and Mechanism of Actions, H1 2020
- Number of Products by Routes of Administration, H1 2020
- Number of Products by Stage and Routes of Administration, H1 2020
- Number of Products by Molecule Types, H1 2020
- Number of Products by Stage and Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AveXis Inc
- Biogen Inc
- Exicure Inc
- F. Hoffmann-La Roche Ltd
- Ionis Pharmaceuticals Inc
- Novartis AG
- Sarepta Therapeutics Inc
- Shift Pharmaceuticals
- Spotlight Innovation Inc
